Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

86 results about "Halothane" patented technology

Halothane sold under the brand name Fluothane among others, is a general anesthetic. It can be used to start or maintain anaesthesia. One of its benefits is that it does not increase the production of saliva, which can be particularly useful in those who are difficult to intubate. It is given by inhalation.

Temperature-sensitive tri-block polymer, reduction and ultrasonic-sensitive core-shell structural microgel with same and application of reduction and ultrasonic-sensitive core-shell structural microgel

The invention belongs to the field of physical chemistry, and provides a temperature-sensitive tri-block polymer, reduction and ultrasonic-sensitive core-shell structural microgel with the same and application of the reduction and ultrasonic-sensitive core-shell structural microgel. The structure of the temperature-sensitive tri-block polymer is PEI<m>-b-PNIPAM<n>-b-PEI<m>, the temperature-sensitive tri-block polymer is amphiphilic at the lower critical solution temperatures (LCST) and can be subjected to self-assembly in aqueous solution to obtain micelle solution with uniform particle sizes in stable states, PNIPAM<n> is used as a core of the micelle solution, and PEI is used as a shell of the micelle solution. Addition can be carried out on micelle and cross-linking agents BAC<y> to obtain reduction-sensitive gel shells, and disulfide bonds on the shells can be selectively cracked by reducing reagents such as GSH, TCEP and DTT. The temperature-sensitive tri-block polymer, the reduction and ultrasonic-sensitive core-shell structural microgel and the application have the advantages that halothane molecules with gas-liquid phase change properties can be loaded, accordingly the core-shell structural microgel with ultrasonic response can be obtained, and the purpose of target medicine administration can be achieved.
Owner:EAST CHINA UNIV OF SCI & TECH

Acrylamide copolymer containing halothane and phosphoric acid ester as well as preparation method and application thereof

The invention relates to an acrylamide copolymer containing halothane and phosphoric acid ester as well as a preparation method and the application thereof. The preparation method comprises the steps of: (1) dissolving monomer, crosslinking monomer and non-fluoro long-chain monomer of the acrylamide copolymer containing halothane and phosphoric acid ester and emulsifier in deionized water and solvent for ultrasonically pre-emulsifying for 1-5h to obtain milk-white pre-emulsion; (2) under the protection of N2, heating 1/3 of the pre-emulsion to 60-90 DEG C, slowly dropping an initiator aqueous solution for initiating reaction, stopping dropping after the emulsion has blue fluorescence, combining the residual initiator aqueous solution with the pre-emulsion, slowing dropping the combined residual initiator aqueous solution and pre-emulsion into reaction liquid, stopping reaction after continuously reacting for 1-5h at 60-90 DEG C, and cooling down to the room temperature to obtain the required emulsion PFPA (Per Fluoro Propionic Anhydride). In the invention, cotton fabric processed by the copolymer emulsion has excellent performances of resisting water, oil and flame, the processing process is simple, and greater development potency is provided.
Owner:DONGHUA UNIV

Inhalational compound anaesthetic agent

InactiveCN104623084ARapid induction of anesthesiaShort duration of anesthesiaPharmaceutical delivery mechanismAnaestheticsRadix AconitiInduction anesthesia
The invention provides an inhalational compound anaesthetic agent. The inhalational compound anaesthetic agent is characterized by comprising an A agent and a B agent, wherein the A agent serves as an inducer and comprises nitrous oxide, sodium chloride, perfume and a compound emulgator; the B agent serves as an anesthesia retaining agent and comprises flos daturae, radix aconiti agrestis, sevoflurane, sodium chloride, perfume and a compound emulgator; according to the A agent, the content of nitrous oxide is 1-5%, the content of the compound emulgator is 15-25%, and the content of the perfume is 0.1-0.3%; according to the B agent, the content of flos daturae is 0.5-0.9g/100mL, the content of radix aconiti agrestis is 0.1-0.5g/100mL, and the content of the sevoflurane is 1.5-2.5%, the content of the compound emulgator is 10-20%, and the content of the perfume is 0.1-0.3%. The inhalational compound anaesthetic agent is simple to operate during use; the A agent can be used for quickly inducing anesthesia and can be directly inhaled by an inhaling device; the B agent is used for retaining anesthesia, can be inhaled by a matched anesthesia machine and can also be infused into the body by other manners; the infusing time and dosage can be flexibly arranged according to the needs of the operation; and the inhalational compound anaesthetic agent can be applied to complex or long-time operation.
Owner:黄玉华

Liver acellular stent construction method based on irreversible electroporation technology

The invention relates to a liver acellular stent construction method based on an irreversible electroporation technology. The method comprises the following steps of 1.1) weighing a rat, carrying outgas inhalation anesthesia by using isoflurane, maintaining the gas inhalation anesthesia, after the anesthesia is effective, disinfecting abdominal skin of the SD rat in a supine position by using 75%alcohol, and opening the abdomen layer by layer to expose the liver; 1.2) clamping a left lateral lobe area of the rat liver by using a caliper type electrode, and performing high-voltage pulsed electric field treatment; 1.3) after the irreversible electroporation treatment is finished, performing transhepatic portal vein catheterization, perfusing with heparinized PBS (Phosphate Buffer Solution), cutting off the subhepatic inferior vena cava until the liver is full and the color is gradually lightened, gradually dissociating tissues and ligaments around the liver, taking down the liver, andimmersing the liver into the heparinized PBS; 1.4) putting the taken liver into a clean container, and performing one-way perfusion with deionized water, and 1.5) after the deionized water perfusion is finished, performing one-way perfusion with PBS for 30 minutes to complete the preparation of the stent. By the method disclosed by the invention, the construction efficiency of the in-vitro acellular stent can be effectively improved under the condition of not applying harmful chemical preparations.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products